An evaluation of RAS testing and survival among mCRC patients in the United States.

被引：0

作者：

Kiprilov, Enko

Sangare, Laura

Lowe, Kimberly

Christodoulopoulou, Alexandra

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] SimulStat, Portland, OR USA

[3] Amgen Inc, Seattle, WA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.e15144

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e15144

引用

页数：1

共 50 条

[1] Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.
Lowe, Kimberly
Kelsh, Michael Anthony
McCarl, Kevin
Bohac, Gerry C.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[2] Survival trends among patients with acute myeloid leukemia in the United States.
Uprety, Dipesh
Ghimire, Krishna Bilas
Nepal, Barsha
Shah, Binay Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] Survival among elderly metastatic breast cancer patients in the United States.
Davis, K. L.
Iyer, S.
Candrilli, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[4] Assessment of treatment with panitumumab, cetuximab, and bevacizumab among mCRC patients with wild-type RAS or BRAF treated at community cancer centers in the United States.
Lowe, Kimberly
Garawin, Tamer
Kelsh, Michael Anthony
Bohac, Gerry C.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[5] Survival trend among patients with advanced pancreatic neuroendocrine tumors in United States.
Kunwor, Ranju
Ghimire, Krishna Bilas
Nepal, Mahesh
Baniya, RamKaji
Ho, Dominic
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Survival of patients with hepatorenal syndrome on dialysis in the United States.
Ahuja, TS
Shaikh, A
Afzal, A
Kuo, YF
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 826A - 826A
[7] Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States.
Agg, Himani
Han, Yimei
Cui, Zhanglin Lin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[8] An assessment of KRAS, NRAS, and BRAF testing prior to 1st line of therapy among mCRC patients treated at community cancer centers in the United States.
Florea, Ana
Garawin, Tamer
Sangare, Laura
Kelsh, Michael Anthony
Lowe, Kimberly
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[9] Survival differences between Hemodialysis and peritoneal dialysis among "Large" ESRD patients in the United States.
Stack, AG
Murthy, BVR
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 500A - 500A
[10] Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States.
Braithwaite, Matthew
Nevala-Plagemann, Christopher Duane
Baron, Kelsey
Haaland, Benjamin
Pappas, Lisa M.
Garrido-Laguna, Ignacio
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →